Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
NCT00489281 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PHASE2 · terminated · last registry update 2019-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible.” | – | Registry record, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IMPDH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-03-13Phase 3 first posted: Mats Heyman, Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses (NCT04307576)
- 2020-02-26Results posted on the registry: Hoffmann-La Roche, Mycophenolate Mofetil/Mycophenolic Acid + Obinutuzumab (NCT02550652)
- 2020-02-11Results posted on the registry: University of British Columbia, Tacrolimus + Tacrolimus (NCT01265537)
- 2020-01-31Results posted on the registry: Alliance for Clinical Trials in Oncology, cyclophosphamide + cytarabine (NCT00558519)
- 2019-08-02Phase 3 first posted: University Hospital Muenster, Cyclophosphamide + Cytarabine (NCT04043494)
- 2019-06-20Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Cyclophosphamide (NCT00408005)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-05-22Phase 3 first posted: Medical College of Wisconsin, Tacrolimus + Methotrexate (NCT03959241)
- 2019-04-26Results posted on the registry: University of California, San Francisco, Mycophenolate mofetil + Methotrexate (NCT01829295)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2019-04-02Phase 3 first posted: Nilratan Sircar Medical College, Rituximab + Mycophenolate Mofetil (NCT03899103)
- 2019-02-04Phase 3 first posted: JHSPH Center for Clinical Trials, Adalimumab (ADA) + Conventional immunosuppression (CON) (NCT03828019)
- 2018-10-25Results posted on the registry: Southern California Institute for Research and Education, Mycophenolate mofetil + Prednisolone (NCT01903798)
- 2018-08-22Phase 3 first posted: Martin Schrappe, Blinatumomab + Bortezomib (NCT03643276)
- 2018-07-30Phase 3 first posted: Medeor Therapeutics, Inc., MDR-102 + Immunosuppressive Agents (NCT03605654)
- 2018-07-03Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Fludarabine + Busulfan (NCT01135329)
- 2018-06-07Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Donor Lymphocyte Infusion (DLI) + Cyclophosphamide (NCT01982682)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision